Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Jeffs’ Brands Enters the Logistics Center Market by Closing Strategic Acquisition of a U.S. Company that Operates a U.S. Based Logistics Center
-
374Water Announces its AirSCWO Technology is Successful in Eliminating LNAPL-Based PFAS from Impacted Groundwater Samples from the U.S. Navy
-
Helport AI Expands AI Solutions for the Insurance Industry with Enhanced Insurance Edition
-
CSW Industrials Announces Definitive Agreement to Acquire Aspen Manufacturing for $313.5 Million, Executing Disciplined Capital Allocation and Strategic Expansion in the HVAC/R End Market
-
Expion360 to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on Monday, March 31, 2025 at 4:30 p.m. Eastern Time
-
Swiss Re to sell 10.05% stake in Definity Financial for CAD 655 million
-
Preferred Bank Announces Approval to Continue Share Repurchase Plan
-
CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025
-
Jackery Showcases Smart Essential Home Backup Solutions & Energy-Efficient Upgrades at National Hardware Show 2025
-
New InStride Health Data Reveals Overall Clinical Improvement in 98% of Youth with Anxiety and/or OCD
-
TransGlobal Assets Inc. (OTC: TMSH) Names Michael Berman as CEO
-
Kids Help Phone continues to Fuel Innovation & Equity in Youth Mental Health with donation from TD Bank Group
-
Vimeo Named a Top 5 Brand in Video Leadership in Fast Company's Most Innovative Companies List
-
Overwatch Expands Cybersecurity Innovation with AI-Driven Hyper-Automation, Delivering Unfair Advantage to MSPs
-
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
-
Vimeo Named a Top 5 Brand in Video Leadership in Fast Company's Most Innovative Companies List
-
Giftify, Inc.’s CardCash Platform Offers Relief on Grocery Bills as Egg Prices Soar in 2025
-
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
-
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
-
Prenetics’ IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market
-
SENSENET AND IEZ! PARTNER TO PROVIDE AI-BASED EARLY WILDFIRE DETECTION SOLUTION TO PREVENT WILDFIRES IN BRAZIL
-
Inspired Entertainment Announces Long-Term Contract Extension with Buzz Bingo
-
Blue Hat Completes 1 Ton Gold Purchase, Surging Gold Prices Boost Book Profits to New Highs
-
IDT Corporation to Present at Sidoti Investor Conference
-
March 2025 Letter to Shareholders
-
Jackery Showcases Smart Essential Home Backup Solutions & Energy-Efficient Upgrades at National Hardware Show 2025
-
FE International Advises on the Acquisition of Cloud Orca by Cooper Parry
-
Outset Medical Announces One-for-Fifteen Reverse Stock Split
-
AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test
-
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
-
Form 8.3 - Assura Plc
-
REE Automotive Announces Pricing of $27 Million Registered Direct Offering of Ordinary Shares
-
Omega Laboratories Reports Completion of Method Validation with Cannabix Technologies Inc. for Marijuana Breath Detection
-
VERSES Demonstrates Smart Building Energy Optimization
-
Form 8.3 - AXA INVESTMENT MANAGERS: Aviva plc
-
Alto Ingredients, Inc. Directors to Not Stand for Reelection
-
KORREKTIONSMEDDELELSE: Aktietilbagekøb i PARKEN Sport & Entertainment A/S: Transaktioner i uge 11
-
Delinea Nears $400M, Demonstrating Strong Growth In Securing AI with Advanced Identity Security
-
Landsbankinn hf.: Covered bond exchange offering results
-
IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025
-
Hill International Appointed as PMO Leader for Athens International Airport’s Airport Expansion Program
-
SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $
-
New Report Highlights 100+ Actionable Strategies for Climate-Resilient Water and Sanitation in Frontline Communities Across US
-
Buxton Takes Next Step in Revolutionizing Consumer Insights with Acquisition of Audiense
-
StepStone Group Announces 2025 Partner and Managing Director Promotions
-
Cytrellis Secures Health Canada and Saudi Food and Drug Authority Approval for ellacor® with Micro-Coring® Technology
-
Foresight Announces the Integration of NVIDIA Jetson Orin into its 3D Perception Systems
-
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
-
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
-
Archipelo Names Former PANW CSO Paul Calatayud as CISO & Chief Strategy Officer, Signaling the Rise of Developer Security Posture Management
